314 related articles for article (PubMed ID: 35060407)
1. An evaluation of costs associated with overall organ damage in patients with systemic lupus erythematosus in the United States.
Bell CF; Ajmera MR; Meyers J
Lupus; 2022 Feb; 31(2):202-211. PubMed ID: 35060407
[TBL] [Abstract][Full Text] [Related]
2. Retrospective Analysis of Disease Severity, Health Care Resource Utilization, and Costs Among Patients Initiating Belimumab for the Treatment of Systemic Lupus Erythematosus.
Lokhandwala T; Coutinho AD; Bell CF
Clin Ther; 2021 Aug; 43(8):1320-1335. PubMed ID: 34243966
[TBL] [Abstract][Full Text] [Related]
3. Healthcare resource utilization and costs in patients with a newly confirmed diagnosis of lupus nephritis in the United States over a 5-year follow-up period.
Bell CF; Wu B; Huang SP; Rubin B; Averell CM; Chastek B; Hulbert EM
BMC Health Serv Res; 2024 May; 24(1):691. PubMed ID: 38822336
[TBL] [Abstract][Full Text] [Related]
4. Impact of early versus late systemic lupus erythematosus diagnosis on clinical and economic outcomes.
Oglesby A; Korves C; Laliberté F; Dennis G; Rao S; Suthoff ED; Wei R; Duh MS
Appl Health Econ Health Policy; 2014 Apr; 12(2):179-90. PubMed ID: 24573911
[TBL] [Abstract][Full Text] [Related]
5. Clinical and economic burden of organ damage among patients with systemic lupus erythematosus in a real-world setting in Germany.
Schultze M; Garal-Pantaler E; Pignot M; Levy RA; Carnarius H; Schneider M; Gairy K
BMC Rheumatol; 2024 May; 8(1):18. PubMed ID: 38755673
[TBL] [Abstract][Full Text] [Related]
6. Real-world treatment patterns, healthcare resource utilisation and costs in patients with systemic lupus erythematosus treated with belimumab: a retrospective analysis of claims data in the USA.
Bell CF; Priest J; Stott-Miller M; Kan H; Amelio J; Song X; Limone B; Noxon V; Costenbader KH
Lupus Sci Med; 2020; 7(1):e000357. PubMed ID: 32341790
[TBL] [Abstract][Full Text] [Related]
7. Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database.
Pelletier EM; Ogale S; Yu E; Brunetta P; Garg J
Clin Ther; 2009 Nov; 31(11):2653-64. PubMed ID: 20110008
[TBL] [Abstract][Full Text] [Related]
8. Healthcare Costs and Utilization for Patients With Systemic Lupus Erythematosus in China: A National Claims Database Study.
He X; Lloyd E; Cooper S; Li L; Chauhan D; Juliao P; Quasny H; Bao C
Value Health Reg Issues; 2023 Sep; 37():88-96. PubMed ID: 37379801
[TBL] [Abstract][Full Text] [Related]
9. The cost of flares among patients with systemic lupus erythematosus with and without lupus nephritis in the United States.
Bell CF; Huang SP; Cyhaniuk A; Averell CM
Lupus; 2023 Feb; 32(2):301-309. PubMed ID: 36542670
[TBL] [Abstract][Full Text] [Related]
10. Disease and economic burden increase with systemic lupus erythematosus severity 1 year before and after diagnosis: a real-world cohort study, United States, 2004-2015.
Jiang M; Near AM; Desta B; Wang X; Hammond ER
Lupus Sci Med; 2021 Sep; 8(1):. PubMed ID: 34521733
[TBL] [Abstract][Full Text] [Related]
11. A Retrospective Administrative Claims Database Evaluation of the Utilization of Belimumab in US Managed Care Settings.
Ke X; Eisenberg Lawrence DF; Oglesby A; Patel J; Kan H; Boggs R
Clin Ther; 2015 Dec; 37(12):2852-63. PubMed ID: 26547483
[TBL] [Abstract][Full Text] [Related]
12. Clinical and economic characterization of mild, moderate, and severe systemic lupus erythematosus: Real-world observation across payer channels in the United States.
Wu SS; Perry A; Tkacz J; Bryant G
J Manag Care Spec Pharm; 2023 Sep; 29(9):1010-1020. PubMed ID: 37610115
[No Abstract] [Full Text] [Related]
13. Healthcare Resource Use and Costs Associated with Organ Damage in Newly Diagnosed Adults with Systemic Lupus Erythematosus in the UK.
Stirnadel-Farrant HA; Golam SM; Naisbett-Groet B; Gibson D; Langham J; Langham S; Samnaliev M
Rheumatol Ther; 2023 Oct; 10(5):1183-1197. PubMed ID: 37400683
[TBL] [Abstract][Full Text] [Related]
14. Predictors of flare-related inpatient or emergency department stay in systemic lupus erythematosus: A real-world analysis of Medicaid claims in the United States.
Wu SS; Perry A; Zimmerman NM; Bryant G
J Manag Care Spec Pharm; 2024 Jan; 30(1):61-70. PubMed ID: 38153861
[TBL] [Abstract][Full Text] [Related]
15. Prolonged oral corticosteroid treatment in patients with systemic lupus erythematosus: An evaluation of 12-month economic and clinical burden.
Huang SP; DerSarkissian M; Gu YM; Duh MS; Wang MJ; Benson J; Vu J; Averell C; Bell CF
J Manag Care Spec Pharm; 2023 Apr; 29(4):365-377. PubMed ID: 36989451
[No Abstract] [Full Text] [Related]
16. Healthcare utilization and costs of systemic lupus erythematosus in Medicaid.
Kan HJ; Song X; Johnson BH; Bechtel B; O'Sullivan D; Molta CT
Biomed Res Int; 2013; 2013():808391. PubMed ID: 23484162
[TBL] [Abstract][Full Text] [Related]
17. Healthcare Resource Utilization and Associated Costs in Patients With Systemic Lupus Erythematosus Diagnosed With Lupus Nephritis.
Bell CF; Wu B; Huang SP; Rubin B; Averell CM; Chastek B; Hulbert EM; Von Feldt J
Cureus; 2023 Apr; 15(4):e37839. PubMed ID: 37214060
[TBL] [Abstract][Full Text] [Related]
18. Healthcare Utilization and Costs of Systemic Lupus Erythematosus by Disease Severity in the United States.
Murimi-Worstell IB; Lin DH; Kan H; Tierce J; Wang X; Nab H; Desta B; Alexander GC; Hammond ER
J Rheumatol; 2021 Mar; 48(3):385-393. PubMed ID: 32611669
[TBL] [Abstract][Full Text] [Related]
19. Frequency, severity and costs of flares increase with disease severity in newly diagnosed systemic lupus erythematosus: a real-world cohort study, United States, 2004-2015.
Hammond ER; Desta B; Near AM; Wang X; Jiang M
Lupus Sci Med; 2021 Sep; 8(1):. PubMed ID: 34556546
[TBL] [Abstract][Full Text] [Related]
20. Real-world medication use and economic outcomes in incident systemic lupus erythematosus patients in the United States.
Kariburyo F; Xie L; Sah J; Li N; Lofland JH
J Med Econ; 2020 Jan; 23(1):1-9. PubMed ID: 31589081
[No Abstract] [Full Text] [Related]
[Next] [New Search]
